Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 9, Issue 2, Pages 149-160Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712590802646936
Keywords
experimental autoimmune encephalomyelitis (EAE); IL-27; inflammation; multiple sclerosis (MS); Th1; Th17
Funding
- National Institutes of Health [5RO1NS0467892, 5RO1AI061818]
- National Multiple Sclerosis Society [FG1645-A-1]
Ask authors/readers for more resources
Background: Multiple sclerosis (MS) is a debilitating neurological disease, characterized by inflammatory demyelination and axonal degeneration in the CNS. Currently approved therapies are partially effective, however safer and more effective treatments are needed. Objective/methods: To assess the therapeutic potential of the heterodimeric cytokine, IL-27 in MS, based on the current literature. Results/conclusions: IL-27 exerts profound anti-inflammatory effects in several infectious and experimental autoimmune models. In particular, suppressive effects on helper T cells, which are implicated in the pathogenesis of MS, suggest that IL-27 may be therapeutically relevant in MS. However, while exciting discoveries have been made, further work is required particularly in human health and disease, to understand the diverse roles of IL-27 and its therapeutic potential.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available